Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACYCLOVIR vs ANEXSIA 7.5/650
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acyclovir is a synthetic nucleoside analog that inhibits viral DNA replication. It is phosphorylated to acyclovir monophosphate by viral thymidine kinase, then converted to acyclovir triphosphate by cellular kinases. Acyclovir triphosphate competes with deoxyguanosine triphosphate for viral DNA polymerase, incorporating into viral DNA and causing chain termination.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
Herpes simplex virus (HSV) infections: genital herpes, herpes labialis, herpes simplex encephalitis, neonatal herpes,Varicella-zoster virus (VZV) infections: chickenpox, herpes zoster (shingles),Mucocutaneous HSV infections in immunocompromised patients,Prophylaxis of HSV and VZV infections in immunocompromised patients
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
400 mg orally twice daily for herpes zoster; 200 mg orally 5 times daily for genital herpes; 5-10 mg/kg intravenously every 8 hours for severe infections.
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
Terminal elimination half-life is 2.5–3.3 hours in adults with normal renal function; increases to 19.5 hours in anuria.
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Acyclovir is partially metabolized by alcohol and aldehyde dehydrogenase. The major metabolite is 9-carboxymethoxymethylguanine (CMMG), which is inactive. Hepatic metabolism is minimal, and the drug is predominantly excreted unchanged in urine via glomerular filtration and tubular secretion.
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for 62-90% of elimination. Fecal elimination is <2%.
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
9–33% bound to plasma proteins (albumin).
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
Vd: 0.5–1.5 L/kg. Distributes widely; crosses blood-brain barrier achieving 50% of plasma CSF concentration.
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
Oral: 15–30% (dose-dependent). Topical: Minimal systemic absorption (<5%).
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
Cr Cl >25 m L/min: no adjustment; Cr Cl 10-25 m L/min: standard dose every 12 hours; Cr Cl <10 m L/min: standard dose every 24 hours.
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
No dose adjustment required for hepatic impairment; no Child-Pugh based modifications established.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
Neonates: 10-20 mg/kg intravenously every 8 hours; Children: 250-600 mg/m² orally 3-5 times daily or 5-10 mg/kg intravenously every 8 hours.
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
Adjust based on renal function; start at low end of dosing range; monitor for neurotoxicity.
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
None. Acyclovir does not have a black box warning.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
Renal impairment: Dose adjustment required for Cr Cl < 50 m L/min; risk of acute renal failure due to crystallization in renal tubules, especially with rapid IV infusion or dehydration,Neurologic toxicity: Elderly patients or those with renal impairment may develop CNS effects (agitation, hallucinations, seizures); use with caution,Hematologic: Rare reports of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) in immunocompromised patients,IV administration: Avoid rapid infusion, ensure adequate hydration to prevent renal damage
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
Hypersensitivity to acyclovir or valacyclovir,Lactation: Caution advised; excreted in breast milk
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
No significant food interactions. High-fat meals may reduce absorption but not clinically significant. Avoid excessive alcohol as it may worsen side effects (e.g., dizziness).
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
Acyclovir is generally considered low risk during pregnancy. Data from the Acyclovir Pregnancy Registry and postmarketing studies do not show an increased risk of major birth defects compared to the general population. However, high-dose IV acyclovir in first trimester for severe infections carries theoretical risk; use only if clearly needed. No known specific fetal risks by trimester beyond those of the underlying infection.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
Acyclovir is excreted into breast milk with a milk-to-plasma ratio (M/P) of approximately 0.6 to 4.1. An exclusively breastfed infant would receive 0.1-1% of maternal dose (or 0.3-0.7 mg/kg/day based on typical maternal 200 mg oral dose), which is below neonatal therapeutic doses. American Academy of Pediatrics considers acyclovir compatible with breastfeeding. Monitor infant for rash or gastrointestinal disturbance.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
Pregnancy does not significantly alter acyclovir pharmacokinetics; no dose adjustment needed for oral or IV acyclovir. Standard dosing regimens for HSV (e.g., 200-400 mg PO TID for genital herpes or 5-10 mg/kg IV q8h for severe infection) are used. In third trimester, increased renal clearance may require slightly higher doses for VZV (typically 800 mg PO 5 times/day), but no formal recommendations for dose increase. Always adjust for renal impairment separately.
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
Acyclovir requires adequate hydration to prevent crystalluria and nephrotoxicity; ensure urine output >500 m L/q8h. For IV acyclovir, infuse over at least 1 hour to avoid renal damage. Dose adjustment required in renal impairment (Cr Cl <50 m L/min). Early initiation (within 72 hours of rash) improves outcomes in herpes zoster. Oral acyclovir has low bioavailability (15-30%); valacyclovir is a prodrug with better absorption.
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
Take acyclovir exactly as prescribed, even if symptoms improve.,Drink plenty of water during treatment to prevent kidney problems.,Start medication at the first sign of outbreak for best results.,Do not share your medication with others.,Avoid sexual contact when lesions are present to prevent transmission.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACYCLOVIR vs ANEXSIA 7.5/650, answered by our medical review team.
ACYCLOVIR is a Antiviral that works by Acyclovir is a synthetic nucleoside analog that inhibits viral DNA replication. It is phosphorylated to acyclovir monophosphate by viral thymidine kinase, then converted to acyclovir triphosphate by cellular kinases. Acyclovir triphosphate competes with deoxyguanosine triphosphate for viral DNA polymerase, incorporating into viral DNA and causing chain termination.. ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACYCLOVIR and ANEXSIA 7.5/650 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACYCLOVIR is: 400 mg orally twice daily for herpes zoster; 200 mg orally 5 times daily for genital herpes; 5-10 mg/kg intravenously every 8 hours for severe infections.. The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACYCLOVIR and ANEXSIA 7.5/650 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACYCLOVIR is classified as Category A/B. Acyclovir is generally considered low risk during pregnancy. Data from the Acyclovir Pregnancy Registry and postmarketing studies do not show an increased risk of major birth defec. ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.